Vilanti

Warnings & Precautions

LABA monotherapy increases the risk of serious asthma-related events. Don't start Vilanterol Trifenatate + Fluticasone Furoate in COPD or asthma that is getting worse suddenly, and don't use it to treat acute symptoms. Don't combine it with another medicine that contains a LABA, because of the risk of overdose. Candida albicans infection of the mouth and pharynx may occur, so monitor patients periodically. Advise the patient to rinse his/her mouth with water after inhalation, without swallowing the water, to help reduce the risk. Patients with COPD have an increased risk of pneumonia, so watch them for signs and symptoms of it. Existing infections can potentially get worse (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex). Use with caution in patients with these infections. Chickenpox or measles can take a more serious or even fatal course in susceptible patients. There is a risk of impaired adrenal function when patients are transferred from systemic corticosteroids. Taper them slowly from the systemic corticosteroid if moving to this inhalation capsule. Hypercorticism and adrenal suppression may occur with very high dosages, or even at the regular dosage in susceptible people. If such changes occur, stop this inhalation capsule slowly. If paradoxical bronchospasm occurs, stop this inhalation capsule and start alternative therapy. Use with caution in patients with cardiovascular disorders because of beta-adrenergic stimulation. Assess bone mineral density at the start and periodically after that, since a decrease can occur. Glaucoma and cataracts may occur with long-term use of ICS. Consider referring patients to an ophthalmologist if they develop ocular symptoms or use this inhalation capsule long term. Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus and ketoacidosis. Increased blood glucose levels have been reported. Also be alert to hypokalemia.